Search research articles
Contact Us
Filters
Showing results (121-130 of 167) with videos related to
Page
of 17
Sort By:
The Lancet. Oncology
|
May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.
Science Advances
|
February 11, 2021
Water heavily fractionated as it ascends on Mars as revealed by ExoMars/NOMAD
Geronimo L Villanueva, Giuliano Liuzzi, Matteo M J Crismani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
Kai He, David Berz, Shirish M Gadgeel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2020
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Komal Jhaveri, Matthew T Chang, Dejan Juric, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, et al.
Leukemia Research
|
September 30, 2023
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
Tamanna Haque, Felix López Cadenas, Blanca Xicoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Funda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Emerson A Lim, Johanna C Bendell, Gerald S Falchook, et al.
Blood Cancer Journal
|
February 6, 2019
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
A Keith Stewart, Amrita Y Krishnan, Seema Singhal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 167) with videos related to
Sort By:
Page
of 17
The Lancet. Oncology
|
May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.
Science Advances
|
February 11, 2021
Water heavily fractionated as it ascends on Mars as revealed by ExoMars/NOMAD
Geronimo L Villanueva, Giuliano Liuzzi, Matteo M J Crismani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
Kai He, David Berz, Shirish M Gadgeel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2020
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers
Komal Jhaveri, Matthew T Chang, Dejan Juric, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, et al.
Leukemia Research
|
September 30, 2023
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
Tamanna Haque, Felix López Cadenas, Blanca Xicoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Funda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Emerson A Lim, Johanna C Bendell, Gerald S Falchook, et al.
Blood Cancer Journal
|
February 6, 2019
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
A Keith Stewart, Amrita Y Krishnan, Seema Singhal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Page
of 17